thanks Richney. this is the quality of input and discussion I'd like this forum to do more of plus it is likely that RSH management reads it as well so we might be able to help shape execution of the strategy albeit in a small way. if we partner with GSK then I'd imagine that goal for Q1 2021 should be commercialisation in UK/Europe where GSK is headquartered. that is, there is no reason for delay in launch in other geographies with similar cultures once we get learnings from Aust. rollout. regarding India, I'd imagine that the complexity in that country would spook a number of cornerstone investors going forward. and Clarkey, well, is he needed under the new strategic direction where target market is respiratory physicians? I suspect not.
RSH Price at posting:
7.5¢ Sentiment: Hold Disclosure: Held
